English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

GW395058, a PEGylated peptide agonist of the thrombopoietin receptor, stimulates megakaryocytopoiesis and has previously been shown to increase platelet counts in vivo. The pharmacokinetics and pharmacodynamics of GW395058 were characterized using a randomized, crossover study in a large‐animal model (dog) of chemotherapy‐induced thrombocytopenia.  Nine beagle dogs received i.v. carboplatin (350 mg/m 2 ) on day 0 and day 28. GW395058 (1.31 mg/kg) ( n  = 6) or vehicle control ( n  = 3) was administered on day 1 and day 29 either as an i.v. bolus or s.c. injection. After i.v. administration, peak concentrations of GW395058 occurred rapidly, while the half‐life averaged approximately 56 h. Bioavailability (± standard deviation) of GW395058 given s.c. was 78.2% (20.9%).  GW395058 (i.v. and s.c.) ameliorated the platelet nadir ( p  = 0.0086) and resulted in a shorter time to recovery compared to the control group. The mean nadir platelet counts following carboplatin administration were 197,000 cells/μl (80,000) for the i.v. GW395058‐dose group, 183,000 cells/μl (72,000) for the s.c.‐dose group and 71,000 cells/μl (38,000) for the vehicle‐alone group.  GW395058 reduced the thrombocytopenic effects of carboplatin in dogs. No GW395058‐related adverse side effects were observed.

stem cells

The Pharmacokinetics and Pharmacodynamics of GW395058, a Peptide Agonist of the Thrombopoietin Receptor, in the Dog, a Large‐Animal Model of Chemotherapy‐Induced Thrombocytopenia